Back to search

Article

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers

2021-10-18

Abstract excerpt

Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harbouring KRAS G12C mutations, but drug resistance frequently develops. Due to the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect anti-tumour immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have characteri...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f4a3817f-d0a2-5de9-87c6-4a5892835eef
DOI
10.1101/2021.10.18.464819
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersDOI 10.1101/2021.10.18.464819
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.Semantic proximity
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity
KRAS G12C inhibition and innate immune targeting.Semantic proximity
Low STING expression in a transplantable Kras <sup>G12D</sup> /P53 <sup>ko</sup> lung cancer model contributes to SiglecF <sup>+</sup> neutrophil and CD103 <sup>+</sup> Treg accumulation in tumorsSemantic proximity
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity
Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity
Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsSemantic proximity
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.Semantic proximity
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.Semantic proximity
The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Semantic proximity
KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.Semantic proximity
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.Semantic proximity
Select a neighboring publication to make it the new centre.